Power Sean A 4
4 · TG THERAPEUTICS, INC. · Filed Jul 22, 2022
Insider Transaction Report
Form 4
Power Sean A
CFO
Transactions
- Award
Common Stock
2022-07-20+75,000→ 643,483 total - Award
Employee Stock Option (right to buy)
2022-07-20+200,000→ 200,000 totalExercise: $7.00Exp: 2027-07-20→ Common Stock, par value $0.001 (200,000 underlying)
Footnotes (3)
- [F1]Reflects a grant of restricted shares, of which 1/3 will vest on 1/1/2023, 1/3 will vest upon U.S. Food and Drug Administration approval of ublituximab as a treatment for patients with relapsing forms of multiple sclerosis, and 1/3 will vest upon approval by the European Medicines Agency of ublituximab.
- [F2]Includes shares of restricted Common Stock, which vest over various time periods.
- [F3]Reflects a grant of options relating to 2021 service and performance, of which 1/2 will vest on 1/1/2024 and 1/2 will vest upon U.S. Food and Drug Administration approval of ublituximab as a treatment for patients with relapsing forms of multiple sclerosis.